Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
ORGANIZATION
Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
Shuji Shirakawa, executive managing director at the National Federation of Health Insurance Societies (Kenporen) and a representative of bill payers at the Central Social Insurance Medical Council (CSIMC; Chuikyo), offered his thoughts on FY2012 NHI pricing reform in an interview…
To read the full story
ORGANIZATION
- Policy Veterans’ Group Calls for Value-Based Pricing for Regenerative Medicine
November 14, 2025
- JPMA Exec Urges Immediate Action on Inflation Pressures as Budget Talks Loom
November 14, 2025
- JPMA’s Yoshida Urges Pro-Innovation Rules to Boost Japan’s Appeal amid MFN Fears
November 11, 2025
- Labor Union Calls for Uniform Hike in Drug Prices, Lawmakers Urge Overhaul
October 29, 2025
- JMA Renews Opposition to Insurance Review for OTC-Like Drugs
October 24, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…